ArticleBlood2019
The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.Blood advances · 2022Pooled it
- Evaluation of heparin gel's effects on stage II pressure ulcers: a randomized controlled trial.European journal of medical research · 2025Trial
- Heparin Can Augment Extracellular Vesicle Yield by Inhibiting Reuptake in Donor Cells During Cell Propagation.Journal of extracellular vesicles · 2026Article
- Seventh Åland Island Meeting on von Willebrand Disease.Haemophilia : the official journal of the World Federation of Hemophilia · 2026Article
- von Willebrand disease: an illustrated review.Research and practice in thrombosis and haemostasis · 2026Review
- Prevascularization of electrospun PCL/PLA scaffolds using human adipose-derived stem and endothelial cells enhances vascular integration and host angiogenesis in vivo.Stem cell research & therapy · 2026Article
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
- Biology of von Willebrand disease.Blood advances · 2026Review
- bFGF-Loaded PDA Microparticles Enhance Vascularization of Engineered Skin with a Concomitant Increase in Leukocyte Recruitment.Bioengineering (Basel, Switzerland) · 2026Article
- Spatiotemporal dynamics of mammalian wound healing.Cell discovery · 2026Review
- Structure and multiple functions of von Willebrand factor.Haematologica · 2026Review
- Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection.Annals of medicine · 2025Article
- High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.Cancer biology & medicine · 2025Article
- Article
- Extracellular matrix ligands modulate the endothelial progenitor cell secretome for enhanced angiogenesis.Acta biomaterialia · 2025Article
- Prognostic nomogram based on coagulation for individualized prediction after radical resection of hepatocellular carcinoma.European journal of medical research · 2025Article
- von Willebrand disease and angiodysplasia: a wider view of pathogenesis in pursuit of therapy.Haematologica · 2025Review
- Progress in the clinical application of allogeneic platelet-rich plasma for diabetic foot treatment.Frontiers in endocrinology · 2025Review
- ABO Blood Group and the Risk and Prognosis of Diffuse Large B-Cell Lymphoma.Cancer management and research · 2025Article
- Contact Cooling-Induced ELOVL4 Enhances Skin Wound Healing by Promoting the Inflammation-to-Proliferation Phase Transition.International journal of biological sciences · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
During wound healing, the distribution, availability, and signaling of growth factors (GFs) are orchestrated by their binding to extracellular matrix components in the wound microenvironment. Extracellular matrix proteins have been shown to modulate angiogenesis and promote wound healing through GF binding. The hemostatic protein von Willebrand factor (VWF) released by endothelial cells (ECs) in plasma and in the subendothelial matrix has been shown to regulate angiogenesis; this function is relevant to patients in whom VWF deficiency or dysfunction is associated with vascular malformations. Here, we show that VWF deficiency in mice causes delayed wound healing accompanied by decreased angiogenesis and decreased amounts of angiogenic GFs in the wound. We show that in vitro VWF binds to several GFs, including vascular endothelial growth factor-A (VEGF-A) isoforms and platelet-derived growth factor-BB (PDGF-BB), mainly through the heparin-binding domain (HBD) within the VWF A1 domain. VWF also binds to VEGF-A and fibroblast growth factor-2 (FGF-2) in human plasma and colocalizes with VEGF-A in ECs. Incorporation of the VWF A1 HBD into fibrin matrices enables sequestration and slow release of incorporated GFs. In vivo, VWF A1 HBD-functionalized fibrin matrices increased angiogenesis and GF retention in VWF-deficient mice. Treatment of chronic skin wounds in diabetic mice with VEGF-A165 and PDGF-BB incorporated within VWF A1 HBD-functionalized fibrin matrices accelerated wound healing, with increased angiogenesis and smooth muscle cell proliferation. Therefore, the VWF A1 HBD can function as a GF reservoir, leading to effective angiogenesis and tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.